Orai1 Inhibitors as Potential Treatments for Pulmonary Arterial Hypertension - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue Circulation Research Année : 2022

Orai1 Inhibitors as Potential Treatments for Pulmonary Arterial Hypertension

David Beech
  • Fonction : Auteur
Marc A Bailey

Résumé

Rationale: Pulmonary arterial hypertension (PAH) is characterized by progressive distal pulmonary artery (PA) obstruction, leading to right ventricular hypertrophy and failure. Exacerbated intracellular calcium (Ca2+) signaling contributes to abnormalities in PA smooth muscle cells (PASMCs), including aberrant proliferation, apoptosis resistance, exacerbated migration, and arterial contractility. Store-operated Ca2+ entry (SOCE) is involved in Ca2+ homeostasis in PASMCs, but its properties in PAH are unclear. Methods: Using a combination of Ca2+ imaging, molecular biology, in-vitro, ex-vivo, and in-vivo approaches, we investigated the roles of the Orai1 SOC channel in PA remodeling in PAH and determined the consequences of pharmacological Orai1 inhibition in vivo using experimental models of pulmonary hypertension (PH). Results: SOCE and Orai1 mRNA and protein were increased in human PASMCs (hPASMCs) from patients with PAH (PAH-hPASMCs). We found that MEK1/2, nuclear factor of activated T cells (NFAT), and nuclear factor-kappa B (NFƘB) contribute to the upregulation of Orai1 expression in PAH-hPASMCs. Using siRNA and Orai1 inhibitors, we found that Orai1 inhibition reduced SOCE, mitochondrial Ca2+ uptake, aberrant proliferation, apoptosis resistance, migration, and excessive calcineurin activity in PAH-hPASMCs. Orai1 inhibitors reduced agonist-evoked constriction in human PAs. In experimental rat models of PH evoked by chronic-hypoxia, monocrotaline, or Sugen/hypoxia, administration of Orai1 inhibitors (BTP2, JPIII, or 5J4) protected against PH. Conclusions: In human PAH and experimental PH, Orai1 expression and activity are increased. Orai1 inhibition normalizes the PAH-hPASMCs phenotype and attenuates PH in rat models. These results suggest that Orai1 should be considered as a relevant therapeutic target for PAH.
Fichier principal
Vignette du fichier
Masson B et al manuscript _HAL.pdf (3.07 Mo) Télécharger le fichier
Origine Fichiers produits par l'(les) auteur(s)

Dates et versions

hal-04432679 , version 1 (01-02-2024)

Identifiants

Citer

Bastien Masson, Hélène Le Ribeuz, Jessica Sabourin, Loann Laubry, Emily Woodhouse, et al.. Orai1 Inhibitors as Potential Treatments for Pulmonary Arterial Hypertension. Circulation Research, 2022, 131 (9), pp.e102-e119. ⟨10.1161/CIRCRESAHA.122.321041⟩. ⟨hal-04432679⟩
52 Consultations
24 Téléchargements

Altmetric

Partager

Gmail Mastodon Facebook X LinkedIn More